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Abstract
Purpose: The poor tissue penetration of visible light has been a major barrier for optical imaging,
photoactivatable conversions, and photodynamic therapy for in vivo targets with depths beyond
10 mm. In this report, as a proof-of-concept, we demonstrated that a positron emission
tomography (PET) radiotracer, 2-deoxy-2-[18F]fluoro-D-glucose (18FDG), could be used as an
alternative light source for photoactivation.
Procedures: We utilized 18FDG, which is a metabolic activity-based PET probe, as a source of
light to photoactivate caged luciferin in a breast cancer animal model expressing luciferase.
Results: Bioluminescence produced from luciferin allowed for the real-time monitoring of
Cherenkov radiation-promoted uncaging of the substrate.
Conclusion: The proposed method may provide a very important option for in vivo photo-
activation, in particular for activation of photosensitizers for photodynamic therapy and
eventually for combining radioisotope therapy and photodynamic therapy.
Key words: Cherenkov radiation, Bioluminescence, Photoactivation, Caged luciferin
Introduction
Photoactivatable conversions such as photosynthesis inplants, photoswitchable chemical reactions, photoacti-
vatable probes for imaging, and photosensitization in photo-
dynamic therapy exist throughout nature and are exploited in
many laboratory techniques. However, the poor tissue
penetrating ability of light undoubtedly limits its broad
application in vivo [1–3]. To address light penetration issues,
long wavelength light sources are often used, but this can
come as a tradeoff with excitation losses due to poor overlap
with absorption spectra. Ideally, incident light for these
applications would exhibit both high-depth penetration and a
high spectral overlap with photoactive molecule’s absorb-
ance spectrum. An emerging way to address depth is to
“move” the light source from outside of the tissue to the
depth where it is co-localized with photoactive agents.
Importantly, placement of an excitation “light source” in
vivo can be accomplished noninvasively with Cherenkov
radiation.
Recently, there has been growing interest in the use of
photons from Cherenkov radiation for optical imaging [4–
12] and for excitation of quantum dots and fluorophores in
vivo [6, 8]. Charged particles such as β+ and β− which are
generated from radioactive isotope decay can result in
visible light with a broad energy range (ca. 6.1 to 1.23 eV,
200–1,000 nm). As a charged particle travels, it can polarize
the molecules of its medium into a high-energy (excited)
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state. When the polarized molecules relax back to the ground
state, they emit light in the form of radiation luminescence.
The spectrum of radiation luminescence consists of contin-
uous wavelengths throughout the ultraviolet and visible
spectrum, with the intensity distribution inversely propor-
tional to the square of the wavelength [4, 5]. The use of this
light for in vivo optical imaging has, to date, been limited to
the lower energy and intensity portion of the continuous
spectrum. To the best of our knowledge, harnessing the
higher intensity portion of the spectrum (200–400 nm) has
not yet been demonstrated.
Photoactivatable conversions, such as photosynthesis in
plants, photoswitchable chemical reactions, photoactivatable
probes for imaging, and photosensitization in photodynamic
therapy are widely observed in nature and have been applied in
many chemical biology applications [13]. We hypothesized
that a radioactive isotope that produces charged particles and
thus Cherenkov radiation could be used as an “internal light
source” to photoactivate caged compounds in vivo. The
radiation luminescence in the higher energy and intensity
portion of the spectrum could be considered as an alternative
for external ultraviolet light, which is necessary for photo-
activation (uncaging; Fig. 1a). Recognizing that many medic-
inal applications of caged drugs have been impeded by the poor
penetrating ability of the light source [13–16], we feel that this
method could provide a critical step forward for in vivo
diagnostics and therapy. Since radioactive isotopes can be
tuned and localized to tissues within the body, the proposed
photoactivation reaction should have no depth limitation.
Obviously, the distribution of an administered radioisotope
within tissue will be an issue, but one that is likely controllable
through chemical modifications. We anticipate that the use of
Cherenkov radiation could have potential clinical value for
therapies and diagnostics associated with many forms of
photoactivatable conversions.
In this proof-of-concept study, we utilized 2-deoxy-2-[18F]
fluoro-D-glucose (18FDG), which is a metabolic activity-based
positron emission tomography (PET) probe [17–19], as a
source of light to photoactivate caged luciferin in a breast
cancer animal model expressing luciferase. Bioluminescence
produced from luciferin allowed for the real-timemonitoring of
Cherenkov radiation-promoted uncaging (Fig. 1a).
In this report, we used luciferin 1-(4,5-dimethoxy-2-
nitrophenyl) ethyl ester (DMNP-luciferin) to demonstrate the
in vitro and in vivo feasibilities of photoactivation with 18FDG.
The 1-(2-nitrophenyl)ethyl functional group has been used
widely as a caging group for various biological molecules [13–
15]. To uncage/photoactivate 1-(2-nitrophenyl)ethyl-bearing
molecules, the covalent bond between the active molecule and
(2-nitrophenyl)ethyl group has to be cleaved by light (Fig. 1b).
Normally, irradiation with 365 nm (ultraviolet) light is used to
photocleave the bond and thus release the active form of a
compound [13–15]. In this report, we demonstrated that the
ester bond could be cleaved by 18FDG.
Materials and Methods
18FDG-Promoted Uncaging in Solution
DMNP-luciferin (25.0 μg, 50.0 nmol, Invitrogen, Molecular
Probes) was suspended in distilled water (1.0 mL) and treated
Fig. 1. A new method for uncaging photoactivateable compounds. a The illustration of the activation processes of caged
active molecules. UV light can be used for uncaging but exhibits limited tissue penetration for in vivo applications. Charged
particles from radioactive decay such as β+ or β− produce radiation luminescence capable of affecting the transformation. In
principal, this approach has limitless tissue-penetrating capability. b The release of luciferin by uncaging reaction from DMNP-
luciferin with UV 365 nm irradiation or with radiation luminescence generated from 18FDG.
C. Ran, et al.: Use of Cherenkov Radiation for In Vivo Photoactivation 157
with 18FDG (500 μCi, IBA Molecular) in water (0.1 mL) in the
dark. The resulting suspension was incubated in the dark at room
temperature for 12 h. LC–MS analysis of the sample was
accomplished using a C18 reversed-phase column on a HP 1100
LC/MSD LC-MS spectrometer.
For light-promoted uncaging, a distilled water solution of
DMNP-luciferin (25.0 μg, 50.0 nmol) was irradiated with UV
365 nm light (UVGL-58 lamp, 6 W). The solution in a 1.5-mL
Eppendorf tube was placed directly under the lamp and irradiated
for 5 min. The delivered UV dose was ∼1.8 kJ/m2. After the UV
treatment, LC–MS was recorded.
Cell Imaging
Luciferase-expressing breast adenocarcinoma cells (MDA-MB-231-
luc-D3H1, Caliper) were seeded in a 96-well black clear-bottom plate
(2,000 cells/well). Cells were incubated with a 100-μl solution from
each of the three treatment groups (n=4 wells/group) as follows: (1) a
solution (1.0 mL) of 18FDG (500 μCi) and DMNP-luciferin (25.0 μg;
for this cell study, before adding to cell media, the solution was kept
for 24 h to deconvolute the signal from the radiation luminescence of
18FDG itself); (2) a solution (1.0 mL) of UV 365 nm irradiated
DMNP-luciferin (25.0 μg); (3) a solution (1.0 mL) of DMNP-luciferin
(25.0 μg) alone. Wells with the above-listed solutions without cells
served as controls. The plate was incubated at 37°C for 5 min and then
imaged using IVIS Spectrum (Caliper, Hopkinton MA). The imaging
parameters were the following: block excitation; open emission filter;
Bin=8, FOV=C, f=1, and exposure time=120 s. The quantification
was based on photon radiance (photon per second per square
centimeter per steradian).
Animal Imaging
Animal Preparation Nude mice (nu/nu, Massachusetts General
Hospital Radiation Oncology breeding facilities) were injected with 2×
106 breast adenocarcinoma cells (MDA-MB-231-luc-D3H1, Caliper)
in the mammary fat pad. Tumors were allowed to grow for 3 weeks.
Imaging Procedure An IVIS Spectrum imaging systemwas used to
record the images (exposure time, 120 s; bin=8, f=1, FOV=D).
Tumor-bearing mice were divided into five groups. In the first group
(n=5), each animal received an i.p. injection of luciferin (0.5 mg/
mouse, Caliper, Hopkinton MA). Imaging was performed before
injection and at 2, 10, 20, 30, 40, and 60 min post-injection. In the
second group (n=6), each animal received an i.p. injection of DMNP-
luciferin (0.5 mg/mouse). Images were acquired before injection and at
10, 30, 60, 90, and 120 min post-injection. The third group of mice
(n=3) was injected i.p. with DMNP-luciferin and the whole bodies
were irradiated with 365 nmUV lamp (UVGL-58, 6W) for 3 min (UV
dose was ∼10.8 kJ/m2) before each image acquisition [20] of the five
imaging time points. Images were acquired before injection and at 10,
30, 60, 90, and 120min after injection. The fourth group of mice (n=5)
was injected with an aqueous solution of 18FDG (400 μCi, 100 μL,
i.p.). Images were acquired before injection and 10, 20, 30, 40, 50, 70,
100, 130, and 160 min post-injection (in Fig. 4b, imaging was started
at 40 min after 18FDG injection). The fifth group of mice (n=6) was
first injected with an aqueous solution of 18FDG (400 μCi, IBA
Molecular, 100 μL, i.p.). Images were acquired before injection and at
10, 20, 30, 40min post-injection. Next, the same animals were injected
with DMNP-luciferin (0.5 mg/mouse, i.p.). Images were acquired at
50, 70, 100, 130, and 160 min post-18FDG injection (i.e., 10, 30, 60,
90, and 120 min post-DMNP-luciferin injection).
Image Analysis A region of interest (ROI) was selected to encircle
the tumor in each mouse. The analysis was performed using ROIs
of the same size. The quantification was based on photon radiance
(photon per second per square centimeter per steradian).
Results
Photoactivation of Caged Luciferin with 18FDG
in Solution
In this report, we first tested whether DMNP-luciferin [21]
could be converted to its active form, luciferin, by using 18FDG
(as a source of Cherenkov radiation luminescence) instead of
365 nm UV light (Fig. 1b). Indeed, incubation of an aqueous
18FDG solution (400 μCi in 1.0 mL) with DMNP-luciferin in
the dark promoted the ester bond cleavage as revealed by LC–
MS analysis (Fig. 2a, b), with a yield of about 25%. Positive
control study where 365 nm UV irradiation was used to
promote the cleavage to release luciferin yielded similar results
(SI Fig. 1), with a yield of about 20%.
Photoactivation of Caged Luciferin with 18FDG
in Cells
To verify that the product of DMNP-luciferin uncaged by
radiation luminescence could serve as an active substrate for
luciferase, we used luciferase-expressing breast adenocarci-
noma cells (MDA-MB-231-luc-D3H1). First, we confirmed
that DMNP-luciferin alone and the products of DMNP-
luciferin uncaging by UV 365 nm light and radiation
luminescence (via 18FDG) had no significant signal without
the cells (Fig. 3a, three lower rows). To image the
bioluminescence of the uncaged luciferin with cells, we
treated DMNP-luciferin with 0.5 mCi 18FDG for 24 h to
ensure the complete decay of 18F before adding to the cell
culture media. This was necessary to avoid the direct
luminescence signal from 18FDG itself (the half-life of
FDG is 109.8 min). Then, the solution was applied to the
cells (Fig. 3a, top row). Cells treated with DMNP-luciferin
irradiated with UV 365 nm light (Fig. 3a, second row from
the top) and cells treated with DMNP-luciferin alone
(Fig. 3a, third row from the top) were used as the positive
and negative controls, respectively. We found that the signal
from the cells treated with the product uncaged by 18FDG
incubation was significantly higher than that from DMNP-
luciferin-treated cells (Fig. 3b) and was similar to the
treatment with the product of UV 365 nm irradiation,
suggesting that radiation luminescence-promoted uncaging
released an active form of luciferin from caged DMNP-
luciferin. Signal from the control wells (Fig. 3a, three lower
rows) was negligible (G10% of the positive control).
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Photoactivation of Caged Luciferin with 18FDG
Radiation Luminescence In Vivo
In this study, we hypothesized that 18FDG could be used in
vivo for uncaging/photoactivation of a substrate in a model
system. To test this hypothesis, we used mice bearing
luciferase-expressing breast tumors. The experimental group
of animals was first injected with 18FDG (0.4 mCi, i.p.)
followed by DMNP-luciferin at 40 min after 18FDG
administration (Fig. 4a). This time point was selected to
allow for 18FDG accumulation, which normally reaches peak
levels in tumors at approximately 1 h post-injection [17]. For
this group, the total signal in tumor site was the sum of
radiation luminescence of 18FDG and bioluminescence of
luciferin released by uncaging (Fig. 4a). Four control groups
were used to support the findings from this study. The first
control group included animals injected with luciferin as a
positive control, which showed the expected BLI signal (SI
Fig. 2). The second control group was injected with only
18FDG to measure the signal from the direct radiation
luminescence of 18FDG (Fig. 4b). The third control group
was injected with DMNP-luciferin and then subjected to ex
Fig. 3. Bioluminescence imaging of MDA-MB-231-luc-D3H1 cells (Caliper). a Rows 1–3 cells were treated with the products of
18FDG-promoted (radiation luminescence) uncaging of DMNP-luciferin, UV 365 nm irradiated DMNP-luciferin, and DMNP-
luciferin (25.0 μg) alone. Rows 4–6 blank controls of the three solutions described above without cells. b Quantitative analysis
of the image in (a). Radiation-luminescence-promoted uncaging and UV-light-promoted uncaging showed significantly higher
bioluminescence signal than that of DMNP-luciferin alone.
Fig. 2. LCMS characterization of luciferin and the products of 18FDG (radiation luminescence) promoted uncaging of DMNP-
luciferin. a LCMS data from analysis of D-luciferin standard (Caliper). Chromatogram has two major peaks, corresponding to a
luciferin water addition product (retention time, 3.7 min) and luciferin (retention time, 5.0 min). The parent ion observed as major
species. b Chromatogram of the products of 18FDG-promoted uncaging reaction of DMNP-luciferin. Peak 1 corresponds to
luciferin hydrate; peak 2—the released luciferin; peak 3—DMNP-luciferin.
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vivo irradiation using 365 nm UV light (Fig. 4c). The final
control group was treated with only DMNP-luciferin to test
the inherent background signal (Fig. 4d).
Our results indicate that the bioluminescence signal from
the tumor of 18FDG-injected animals significantly increased
after DMNP-luciferin administration (Fig. 4a). The signal from
tumors in the 18FDG-only control group increased gradually
until peaking around 40 min. This is consistent with PET
imaging results reported by Fueger (SI Fig. 3, full-time course
is shown) [17]. The signal in the experimental group (DMNP-
luciferin+18FDG) was 12.5-fold higher of that in the 18FDG-
only group and reached its peak at 70 min post-DMNP-
luciferin injection (Fig. 4e). Our data suggest that the radiation
luminescence signal from 18FDG contributed to only about 8%
of the total signal observed in the experimental group. The
contribution of background to the signal as determined by the
DMNP-luciferin-only control group (Fig. 4d) was approx-
imately 5% of the highest signal observed in the experimental
group (Fig. 4e). Taken together, our data suggested that 18FDG,
which had accumulated in the tumor, had a remarkable capacity
to uncage DMNP-luciferin and thus release the active substrate
for luciferase.
As expected, we found that irradiation with 365 nm
light could indeed activate caged luciferin (Fig. 4c),
similar to previously reported findings [20]. However,
the signal in this group was only slightly higher than that
of DMNP-luciferin-only group (Fig. 4d) and significantly
lower than the signal from the experimental group,
indicative of the low penetrating ability of UV light for
in vivo uncaging.
Discussion
Although radiation luminescence from charged particles has
been used successfully for in vivo optical imaging [4, 5], to
the best of our knowledge, its application beyond imaging
has not yet been explored. In this proof-of-concept report,
we demonstrated that the phenomenon of radiation lumines-
Fig. 4. Luminescence imaging of tumor-bearing mice subjected to different treatments regimens. The tumor in each group
was marked with red circle in the first image. a Mice were first treated with 18FDG and then with DMNP-luciferin 40 min later.
Images are from 0 min (pre-injection), 10, 30, 60, 90, and 120 min post-injection of DMNP-luciferin. b Mice were injected with
18FDG only. For comparison purposes, images shown here were obtained 40 min after 18FDG injection (for the whole-time
18FDG course, see SI Fig. 3). cMice were treated with DMNP-luciferin and irradiated with UV 365 nm light for 3 min before each
image acquisition. d Mice were i.p. injected with DMNP-luciferin only. e Quantitative analysis of the images in (a–d). The signal
from the group treated with both 18FDG and DMNP-lucferin (red line) was significantly higher than that of DMNP-luciferin alone
group (black line), UV irradiated group (blue line), or 18FDG only group (green line).
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cence could be used for photoactivatable chemical conver-
sion. This suggests that a radioactive isotope could serve as
an alternative “light source,” which could be used to
overcome the tissue penetrating inadequacy of conventional
light sources. We believe that our approach will open new
directions for various light-promoted conversions, particu-
larly for in vivo applications.
It has been shown recently that the 400–500-nm
portion of the continuous spectrum of radiation lumines-
cence could be used to excite quantum dots in vitro and in
vivo [5–8]. However, the exact excitation mechanism of
this phenomenon is still not clear. Cherenkov resonance
energy transfer [6] to quantum dots and the excitation of
quantum dots by radiation luminescence are likely the
major contributors. In our experiments, the observed
uncaging effect could probably be ascribed to: (1)
Cherenkov (i.e., radiation luminescence), (2) direct inter-
action/polarization by positrons, (3) scintillation light from
positron interaction with the media and container. How-
ever, it is not possible at this point to experimentally
verify this assumption.
The application of the technology that we have described
is certainly not limited to photo-uncaging of molecules in
vivo with 18FDG. Previously, it was demonstrated that in
addition to radionuclides that generate β+ particles (such as
18F and 64Cu), β− emitters such as 131I and 90Y could be
used for optical imaging [5]. In this report, we demonstrated
that radiation luminescence generated by 18FDG was
capable of activating caged luciferin in vivo; thus, a natural
extension of this work is the use of other radionuclides,
which emit either β+ or β− particles, for the same reaction.
Similarly, this approach could be used for other photo-
conversions including photodynamic therapy, which we are
currently exploring. We expect this could increase the
efficacy of such treatments. Most photosensitizers of photo-
dynamic therapy have to be activated using light in the near-
infrared range [1–3]. However, porphyrin compounds, the
drugs that are most commonly used in photodynamic
therapy, exhibit stronger absorption and excitation in the
range of 400–600 nm [22–24]. Radiation luminescence
could be used to excite molecules for photodynamic therapy
in this higher energy portion of the spectrum.
We anticipate a possible synergy between photodynamic
therapy and administration of therapeutic radioisotopes
given that excitation of photosensitizers could occur by
local radiation luminescence. This has not been explored
despite the fact that photodynamic and radioisotope thera-
pies are widely used in combination for surface tumors. To
date, the synchronized combination of the two has not been
practiced widely. We feel that concurrent treatment with a
therapeutic radioisotope with unlimited depth penetration
and photodynamic therapy using a photosensitizer could be
synergistic and could produce clinical benefits not only for
surface tumors but also for deep tumors. By extension,
proton therapy, which both uses and produces charged
particles (such as positrons [25]), could likely be harnessed
to excite a photosensitizer in photodynamic therapy, thus
enhancing the overall therapeutic efficacy.
Conclusion
In summary, in this proof-of-principle study, we have
demonstrated that Cherenkov radiation may have chemical
and therapeutic applications beyond radiation luminescence
optical imaging. We accomplished this using a straightfor-
ward DMNP-luciferin uncaging experiment, which showed
that Cherenkov radiation from 18FDG could serve as an
internal “light source” for photoactivation. We are currently
exploring the application of this finding to new imaging and
therapeutic strategies. However, challenges associated with
optimization of radiation dose for maximum effect should be
considered, especially when the radiation risk may limit the
utility of this approach.
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